JP2024532677A - 水溶性プロドラッグ、複合体およびその使用 - Google Patents

水溶性プロドラッグ、複合体およびその使用 Download PDF

Info

Publication number
JP2024532677A
JP2024532677A JP2024505333A JP2024505333A JP2024532677A JP 2024532677 A JP2024532677 A JP 2024532677A JP 2024505333 A JP2024505333 A JP 2024505333A JP 2024505333 A JP2024505333 A JP 2024505333A JP 2024532677 A JP2024532677 A JP 2024532677A
Authority
JP
Japan
Prior art keywords
moiety
compound
oligo
cancer
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532677A5 (https=
Inventor
シャバット、ドロン
サッチ－ファイナロ、ロニット
スウィーネイ－ラシュ、スタンレイ
ドイチュ、カール
ベルガー、ニール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2024532677A publication Critical patent/JP2024532677A/ja
Publication of JP2024532677A5 publication Critical patent/JP2024532677A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024505333A 2021-07-28 2022-07-20 水溶性プロドラッグ、複合体およびその使用 Pending JP2024532677A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL285208 2021-07-28
IL28520821 2021-07-28
PCT/IL2022/050782 WO2023007481A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532677A true JP2024532677A (ja) 2024-09-10
JP2024532677A5 JP2024532677A5 (https=) 2025-07-23

Family

ID=85086377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505333A Pending JP2024532677A (ja) 2021-07-28 2022-07-20 水溶性プロドラッグ、複合体およびその使用

Country Status (7)

Country Link
EP (1) EP4377292A1 (https=)
JP (1) JP2024532677A (https=)
CN (1) CN117999254A (https=)
AU (1) AU2022318483A1 (https=)
CA (1) CA3226393A1 (https=)
IL (1) IL310354A (https=)
WO (1) WO2023007481A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040856A2 (en) * 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2020086858A1 (en) * 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
JP2020527599A (ja) * 2017-07-04 2020-09-10 イントゥーセル，インコーポレーティッド 切断可能なリンカーを含む化合物及びその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040856A2 (en) * 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP2020527599A (ja) * 2017-07-04 2020-09-10 イントゥーセル，インコーポレーティッド 切断可能なリンカーを含む化合物及びその使用
WO2020086858A1 (en) * 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEMISTRY, vol. 30, JPN6026013484, 2019, pages 1969 - 1978, ISSN: 0005834974 *
BIOCONJUGATE CHEMISTRY, vol. 32, JPN6026013485, 13 April 2021 (2021-04-13), pages 983 - 990, ISSN: 0005834975 *

Also Published As

Publication number Publication date
CN117999254A (zh) 2024-05-07
EP4377292A1 (en) 2024-06-05
IL310354A (en) 2024-03-01
AU2022318483A1 (en) 2024-02-22
WO2023007481A1 (en) 2023-02-02
CA3226393A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JP7753372B2 (ja) 重水素化カンプトテシン系誘導体及びその抗体薬物複合体
JP7686677B2 (ja) 高安定性の親水性結合ユニットを有するカンプトテシン類薬物及びその複合体
CN113766954B (zh) 喜树碱衍生物
JP2024038168A (ja) 生物活性分子コンジュゲート、その調製法及び使用
CN112752759A (zh) 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途
KR20240120744A (ko) 캄프토테신 화합물 및 이의 접합체
TWI778059B (zh) 新穎之肽連接子與念珠藻素接合物，其製備方法及治療之用途
CN111065623A (zh) 用于抗体药物缀合物的接头
TWI714661B (zh) 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN106170303A (zh) 通过半胱天冬酶激活的前体药物
EP4429707B1 (en) ANTHRACYCLINE-DERIVED BINDING REAGENTS, ANTIBODY-DRUG CONJUGATES AND PROCESSES
JP2025523117A (ja) リンカー、コンジュゲート及びその用途
TW202506105A (zh) 連接子－藥物分子及抗體藥物偶聯物、其製備方法和應用
CN109790178B (zh) 新颖细胞毒性剂和其缀合物
JP2024532677A (ja) 水溶性プロドラッグ、複合体およびその使用
WO2025031923A1 (en) Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
JP6817956B2 (ja) 新規なグルタミン酸誘導体とブロック共重合体を含有する組成物及びその用途
AU2016226083A1 (en) Cyclic peptide analogs and conjugates thereof
HK40111022A (zh) 水溶性前药、偶联物及其用途
KR20250019081A (ko) 약물 링커 접합체의 제조 방법 및 이의 중간체
JP6487422B2 (ja) 新しい抗腫瘍剤としてのチエノ［２，３−ｅ］インドール誘導体
WO2025077572A1 (zh) 一种用于前药给药系统的可裂解连接体化合物及其制备和应用
TW202539740A (zh) 包含喜樹鹼衍生物之抗組織因子抗體－藥物綴合物
TW202613076A (zh) 鏈接子－有效負載、由其作成之抗體－藥物共軛物及其用途
CN121652224A (zh) 多肽偶联化合物、所得多肽偶联药物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240325

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407